Two dose levels of ifosfamide in malignant mesothelioma.
Thirty-one consecutive patients with histologically proven and symptomatic malignant mesothelioma were treated with two dose levels of ifosfamide. The first group of 15 patients were given 2.3 g/m2/day for 5 days (group A) and the following 16 patients were treated with 1.2 g/m2/day for 5 days of ifosfamide (group B). Treatment cycles were repeated every 3 weeks. While the partial response rate (PR) in group A was 38.5%, it was only 6.25% in group B (P > 0.05). The 95% confidence interval for the difference in PR rates was 3.3-61.2% > The overall survival (OAS) of groups A and B were similar (8 months and 9 months, respectively). Higher Grade 3-4 myelotoxicity was observed in group A when compared to group B (30.8% vs. 18.7%; P > 0.05). In conclusion, a favourable response rate could be achieved in malignant mesothelioma with high dose ifosfamide at the cost of increased toxicity.
Içli
F
F
Ankara University Medical School, Ibn-i Sing Hospital, Medical Oncology Department, Ankara, Turkey.
Karaoğuz
H
H
Hastürk
S
S
Kurt
B
B
Akbulut
H
H
Dinçol
D
D
Demirkazik
A
A
Cay
F
F
Akyar
S
S
D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy*; D008875:Middle Aged
D018906:Antineoplastic Agents, Alkylating; D007069:Ifosfamide